On Friday of last week, Novan just hit a new 52 week high at $1.36
The Novan company is developing a inhalant for Nitric Oxide for COVID-19 with Catalent.
Based on the scientific literature and data available to-date with berdazimer sodium and Novan’s product candidate SB206, Novan believes that nitric oxide may inhibit viral replication by disrupting protein function critical for viral replication and infection through generation of reactive intermediates
You can read more here.
Novan recently presented a presentation at HC Wainright’s Virtual Investor KOL Round Table on January 11th:
